Tuesday, June 18, 2013

• Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based CareersBusiness Wire( (Tue 9:00AM EDT)

Monday, June 17, 2013

• Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire( (Mon, Jun 17)

Saturday, June 15, 2013

• Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple MyelomaBusiness Wire( (Sat, Jun 15)

Friday, June 14, 2013

• AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®Business Wire( (Fri, Jun 14)
• Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in ChinaBusiness Wire( (Fri, Jun 14)
• Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in ChinaPR Newswire( (Fri, Jun 14)

Wednesday, June 12, 2013

• AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based TherapiesBusiness Wire( (Wed, Jun 12)

Tuesday, June 11, 2013

• ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid ArthritisBusiness Wire( (Tue, Jun 11)
• ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid ArthritisPR Newswire( (Tue, Jun 11)

Thursday, June 6, 2013

• Health Canada Expands Indications of Abilify® (aripiprazole), to be the First Add-On Treatment for Major Depressive Disorder (MDD)CNW Group( (Thu, Jun 6)
• Health Canada Expands Indications of Abilify® (aripiprazole), to be the First Add-On Treatment for Major Depressive Disorder (MDD)PR Newswire( (Thu, Jun 6)

Wednesday, June 5, 2013

• Bristol-Myers Squibb to Take Part in Goldman Sachs Global Healthcare ConferenceBusiness Wire( (Wed, Jun 5)

Tuesday, June 4, 2013

• U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca’s Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of LipodystrophyBusiness Wire( (Tue, Jun 4)